Zhe Hui Xu

Zhe Hui Xu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2025 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
SYSizuo Yan
Sizuo Yan
YGYu Gan
Yu Gan
ZXZhe Hui Xu
Zhe Hui Xu
HPHaozhe Piao
Haozhe Piao
Cancer is a major killer threatening modern human health and a leading cause of death worldwide. Due to the heterogeneity and complexity of cancer, traditional treatments have limited effectiveness. To address this problem, an increasing number of researchers and medical professionals are working to develop new ways to treat cancer. Bacteria have chemotaxis that can target and colonize tumor tissue, as well as activate anti-tumor immune responses, which makes them ideal for biomedical applications. With the rapid development of nanomedicine and synthetic biology technologies, bacteria are extensively used as carriers for drug delivery to treat tumors, which holds the promise of overcoming the limitations of conventional cancer treatment regimens. This paper summarizes examples of anti-cancer drugs delivered by bacterial carriers, and their strengths and weaknesses. Further, we emphasize the promise of bacterial carrier delivery systems in clinical translation.

1 July 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
YGYu Gan
Yu Gan
YYYingying Yu
Yingying Yu
ZXZhe Hui Xu
Zhe Hui Xu
HPHaozhe Piao
Haozhe Piao
Glioma is a primary malignant tumor in the central nervous system. In recent years, the treatment of glioma has developed rapidly, but the overall survival of glioma patients has not significantly improved. Due to the presence of the blood–brain barrier and intracranial tumor barrier, many drugs with good effects to cure glioma in vitro cannot be accurately transported to the corresponding lesions. In order to enable anti-tumor drugs to overcome the barriers and target glioma, nanodrug delivery systems have emerged recently. It is gratifying that liposomes, as a multifunctional nanodrug delivery carrier, which can be compatible with hydrophilic and hydrophobic drugs, easily functionalized by various targeted ligands, biodegradable, and hypoimmunogenic in vivo, has become a quality choice to solve the intractable problem of glioma medication. Therefore, we focused on the liposome nanodrug delivery system, and summarized its current research progress in glioma. Hopefully, this review may provide new ideas for the research and development of liposome-based nanomaterials for the clinical treatment of glioma.

31 May 2025 in Phytomedicine
Verified
Journal Article
Open access
ZXZhe Hui Xu
Zhe Hui Xu
ZWZhisheng Wu
Zhisheng Wu
JTJiamei Tang
Jiamei Tang
YGYu Gan
Yu Gan
JLJicheng Li
Jicheng Li
HPHaozhe Piao
Haozhe Piao
Glioblastoma (GBM) is the most malignant primary intracranial tumor. Owing to its unfavorable prognosis and frequent recurrence, patient outcomes are poor even with standard treatment. Recent studies have reported that FTY720, a structurally modified sphingosine extracted from Cordyceps sinensis, has preclinical antitumor efficacy and can regulate the microenvironment of GBM. However, the mechanism and effective utilization of FTY720, i.e., avoiding adverse reactions during systemic application in GBM remain unclear. This study aimed to investigate the mechanisms by which FTY720 suppresses GBM growth and to explore the ability of a novel liposomal nanoparticle carrying FTY720 to directly target GBM. Molecular, cytological, and histological techniques were employed to assess the effects of FTY720 on GBM cells, both in vitro and in vivo. Ferroptosis induction and its regulatory mechanisms were explored using a combination of reactive oxygen species (ROS), malondialdehyde (MDA) and glutathione (GSH) assays; transmission electron microscopy (TEM); and orthotopic GBM mouse model experiments. A nanoparticle drug delivery system based on liposomes (GF2-FTY720-LPs) was synthesized by thin film dispersion. Our study revealed that FTY720 induces ferroptosis in GBM cells through the AMPK-mTOR-GPX4 pathway, and that ginsenoside F2 (GF2) plays a synergistic role by reducing GSH levels. GF2-FTY720-LPs show superior targeting ability and potent inhibition of GBM in vivo, penetrating the blood-brain barrier and overcoming the shortcomings of systemic FTY720 application. Our findings revealed the inhibitory effect of FTY720 on GBM, and the great ability of GF2-FTY720-LPs to target GBM. GF2-FTY720-LPs penetrate the blood-brain barrier without relying on specific conditions such as a magnetic field, light, or heat. GF2-FTY720-LPs achieved precise localization by targeting the highly expressed GLUT1 in GBM cells, and efficiently released drugs in the acidic tumor microenvironment, which significantly reduced the off-target toxicity and enhanced the antitumor efficacy compared with traditional chemotherapy drugs. In summary, our study provides new insights and a theoretical basis for selecting and researching GBM treatment.

22 October 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
NWNing Wang
Ning Wang
YYYiru Yuan
Yiru Yuan
THTianhao Hu
Tianhao Hu
ZXZhe Hui Xu
Zhe Hui Xu
HPHaozhe Piao
Haozhe Piao
Gliomas are malignant tumors originating from both neuroglial cells and neural stem cells. The involvement of neural stem cells contributes to the tumor’s heterogeneity, affecting its metabolic features, development, and response to therapy. This review provides a brief introduction to the importance of metabolism in gliomas before systematically categorizing them into specific groups based on their histological and molecular genetic markers. Metabolism plays a critical role in glioma biology, as tumor cells rely heavily on altered metabolic pathways to support their rapid growth, survival, and progression. Dysregulated metabolic processes, involving carbohydrates, lipids, and amino acids not only fuel tumor development but also contribute to therapy resistance and metastatic potential. By understanding these metabolic changes, key intervention points, such as mutations in genes like RTK, EGFR, RAS, and IDH can be identified, paving the way for novel therapeutic strategies. This review emphasizes the connection between metabolic pathways and clinical challenges, offering actionable insights for future research and therapeutic development in gliomas.

10 October 2025 in International Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
JSJi Shi
Ji Shi
DZDuo Zheng
Duo Zheng
BYBing Yao
Bing Yao
QLQiang Liu
Qiang Liu
ZXZhe Hui Xu
Zhe Hui Xu
HPHaozhe Piao
Haozhe Piao
In cancer research, the transmembrane (TMEM) family of proteins has attracted considerable attention due to its role in tumor progression and chemoresistance. These membrane proteins are integral to cellular processes, including signal transduction, ion transport and cellular homeostasis, rendering them promising therapeutic targets. The TMEM proteins are implicated in several types of cancer, including breast, ovarian, lung and thyroid cancer, where they regulate numerous cellular processes, including proliferation, migration, invasion and survival. Notably, TMEM45A and TMEM158 contribute to resistance to platinum‑based chemotherapy by increasing the expression of proteins associated with hypoxic conditions and multidrug resistance. Additionally, epigenetic regulation, particularly promoter methylation of TMEM88, is pivotal in regulating TMEM88 expression and function in chemoresistance. The present review presents a systematic and comprehensive overview of the structural features, biological functions and regulatory mechanisms of key TMEM proteins across various types of cancer. It also highlights emerging connections between TMEM proteins and the tumor microenvironment, emphasizing their potential as promising therapeutic targets. The novel findings underscore the key role of the TMEM protein family in overcoming chemoresistance and lay a foundation for the development of targeted therapeutic strategies in cancer treatment.

29 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ZXZhe Hui Xu
Zhe Hui Xu
YZYe Zhang
Ye Zhang
JLJia Liu
Jia Liu
JCJing Cui
Jing Cui
YGYu Gan
Yu Gan
HPHaozhe Piao
Haozhe Piao
UM-164 is a dual inhibitor of c-Src and p38 MAPK, and has been a lead compound for targeting triple-negative breast cancer. UM-164 shows stronger binding to the active sites of Src compared with the conventional Src inhibitor Dasatinib. While Dasatinib has displayed some inhibitory effects on glioma growth in clinical trials, whether UM-164 can suppress glioma growth has not been reported. Here we show that UM-164 suppressed the proliferation, migration and spheroid formation of glioma cells, and induced cell cycle arrest in the G1 phase. Moreover, UM-164 triggered YAP translocation to the cytoplasm and reduced the activity of YAP, as evidenced by a luciferase assay. Accordingly, UM-164 markedly decreased the expression levels of YAP target genes CYR61 and AXL. Importantly, ectopic expression of wild-type YAP or YAP-5SA (YAP constitutively active mutant) could rescue the anti-proliferative effect induced by UM-164. Intriguingly, p38 MAPK appears to play a greater role than Src in UM-164-mediated inhibition of YAP activity. Furthermore, the in vitro anti-glioma effect mediated by UM-164 was confirmed in a xenograft glioma model. Together, these findings reveal a mechanism by which UM-164 suppresses the malignant phenotypes of glioma cells and might provide a rationale for UM-164-based anti-glioma clinical trials.